SUMMARY
Following an application from Lycotec Ltd, submitted pursuant to Article 14 of Regulation (EC) No 1924 No /2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to "L-tug lycopene" and reduction of blood low-density lipoprotein (LDL)-cholesterol.
The scope of the application was proposed to fall under a health claim referring to disease risk reduction. The application included a request for the protection of proprietary data.
The food that is the subject of the health claim is L-tug lycopene (i.e. Lyc-O-Mato® embedded in fatrich matrices by a manufacturing process claimed as proprietary and confidential by the applicant). The Panel considers that the food, L-tug lycopene, which is the subject of the health claim, is sufficiently characterised.
The claimed effect proposed by the applicant is "decreases blood cholesterol and triglycerides levels". Therefore, "L-tug lycopene" is the substance, "LDL-cholesterol" is the risk factor and "coronary heart disease" (CHD) is the human disease. The target population proposed by the applicant comprises "healthy adults who wish to lower their blood cholesterol levels". In reply to a request from the European Food Safety Authority (EFSA), the applicant confirmed that the health relationship proposed is related to lowering LDL-cholesterol concentrations, which decreases the risk of CHD. The Panel considers that reduction of blood LDL-cholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.
The applicant identified eight unpublished human intervention studies as pertinent to the claim.
The eight human intervention studies provided were conducted with L-tug lycopene in different food matrices, followed similar protocols, and, as indicated by the applicant, were exploratory in nature. The Panel notes that the information provided was insufficient to allow a scientific evaluation of the studies, and therefore EFSA requested that the applicant provide the full study reports. In reply, the applicant claimed that no additional information on the studies existed.
From the limited information available in the application, the Panel notes that the studies were not randomised and that some methodological aspects, such as the definition of primary outcome(s), power calculations, treatment of missing data, compliance or correction for multiplicity of outcomes, were not considered in the study reports, possibly because of the exploratory nature of these studies, as claimed by the applicant. The Panel also notes that, for one of the studies, a number of discrepancies exist between the version provided to EFSA and the published version, regarding the number of subjects included, the participant flow and the presence or absence of randomisation. The Panel considers that no conclusions can be drawn from these studies for the scientific evaluation of the claim.
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of L-tug lycopene and reduction of blood LDL-cholesterol. 4 harmonises the provisions that relate to nutrition and health claims, and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and claims referring to children's development and health in a Community list of permitted claims.
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).
STEPS TAKEN BY EFSA
 The application was received on 27/08/2014.  The scope of the application was proposed to fall under a health claim referring to disease risk reduction.
 The scientific evaluation procedure started on 07/11/2014.  During its meeting on 06/02/2015, the NDA Panel, having evaluated the data submitted, adopted an opinion on the scientific substantiation of a health claim related "L-tug lycopene" and reduction of blood LDL-cholesterol.
TERMS OF REFERENCE
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16(3) of Regulation (EC) No 1924 No /2006 . On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to "L-tug lycopene" and reduction of blood LDL-cholesterol.
EFSA DISCLAIMER
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of "L-tug lycopene", a positive assessment of its safety, nor a decision on whether "L-tug lycopene" is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924 No /2006 request from the European Food Safety Authority (EFSA), the applicant confirmed that the health relationship proposed is related to lowering low-density lipoprotein (LDL)-cholesterol concentrations, which decreases the risk of CHD.
CHD is a leading cause of mortality and morbidity in European populations, with over 1.9 million deaths in the European Union and over 4.35 million deaths in Europe each year (Pedersen et al., 2005) . Elevated blood cholesterol is an important modifiable risk factor in the development of CHD (WHO, 2002a, b) . It has been shown that blood cholesterol concentrations can be decreased by drugs and by dietary and lifestyle changes (Ornish et al., 1998; Gordon, 2000; Denke, 2005; van Horn et al., 2008) .
The Panel considers that reduction of blood LDL-cholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.
Scientific substantiation of the claimed effect
The applicant stated that, as L-tug lycopene is a recent innovation, only proprietary, unpublished studies were available. The applicant identified eight unpublished human intervention studies as pertinent to the claim (Petyaev et al., unpublished) . One of these studies was published during the evaluation of the application (Petyaev et al., 2014) .
The eight human intervention studies provided were conducted with L-tug lycopene in different food matrices, followed similar protocols, and, as indicated by the applicant, were exploratory in nature. The Panel notes that the information provided was insufficient to allow a scientific evaluation of the studies, and therefore EFSA requested that the applicant provide the full study reports. In reply, the applicant indicated that no additional information on the studies existed.
From the limited information available in the application, the Panel notes that the studies were not randomised and that some methodological aspects, such as the definition of primary outcome(s), power calculations, treatment of missing data, compliance or correction for multiplicity of outcomes were not considered in the study reports, possibly because of the exploratory nature of these studies, as claimed by the applicant. The Panel also notes that for one of the studies, a number of discrepancies exist between the version provided to EFSA (Petyaev et al., unpublished) and the published version (Petyaev et al., 2014) regarding the number of subjects included, the participant flow and the presence or absence of randomisation. The Panel considers that no conclusions can be drawn from these studies for the scientific evaluation of the claim.
The Panel concludes that a cause and effect relationship has not been established between the consumption of L-tug lycopene and reduction of blood LDL-cholesterol concentrations.
CONCLUSIONS
On the basis of the data presented, the Panel concludes that:
 The food, L-tug lycopene (i.e. Lyc-O-Mato® embedded in fat-rich matrices by a manufacturing process claimed as proprietary and confidential by the applicant), which is the subject of the health claim is sufficiently characterised.
 The claimed effect is "lowering low-density lipoprotein (LDL)-cholesterol concentrations, which decreases the risk of coronary heart disease". The target population as proposed by the applicant comprises "healthy adults who wish to lower their blood cholesterol levels". Reduction of blood LDL-cholesterol concentrations is a beneficial physiological effect. A reduction in blood LDL-cholesterol concentrations reduces the risk of CHD.
 A cause and effect relationship has not been established between the consumption of L-tug lycopene and reduction of blood LDL-cholesterol concentrations.
